Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain

NCT00236145 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Breakthrough Pain

Interventions

DRUG: ACTIQ (Oral transmucosal fentanyl citrate)

Sponsor

Cephalon